Si-Cong Ma

6PUBLICATIONS
27CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersMolecular targetsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 05, 2026
CRTAM inhibition mitigates toxicity of immune checkpoint inhibitors without antitumor efficacy trade-off.

Si-Cong Ma, Zi-Xuan Rong, Zi-Peng Xu

|Oct 08, 2024
HLA diversity unveils susceptibility and organ-specific occurrence of second primary cancers: a prospective cohort study.

Zi-Xuan Rong, Wei Wei, Qin Zeng

|Mar 27, 2024
Regular Use of Aspirin and Statins Reduces the Risk of Cancer in Individuals with Systemic Inflammatory Diseases.

Jia-Run Lin, Duan-Duan Han, Wei Wei

|Mar 04, 2023
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy.

Xue Bai, Ze-Qin Guo, Yan-Pei Zhang

|Dec 13, 2022
PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer.

Li-Li Long, Si-Cong Ma, Ze-Qin Guo

|Jul 02, 2020
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

Xue Bai, De-Hua Wu, Si-Cong Ma

Pageof 1

Frequent Collaborators

5 joint publications

Zhong-Yi Dong

4 joint publications

Yan-Pei Zhang

4 joint publications

De-Hua Wu

2 joint publications

Zi-Xuan Rong